Abstract
Originally, nuclear medicine focused on radiopharmaceuticals trapped in organ structures, based on their function, and the presence of disease was seen by the absence of radioactivity. More recently, target-specific radiopharmaceuticals have been developed to visualize and/or treat oncological diseases. Since radiopharmaceuticals have historically a leading position in the search for “molecular imaging”, it would be a waste not to learn from the pitfalls and opportunities that have been and are found during the development of radiopharmaceuticals. This knowledge can be used in the improvement of contrast agents for other imaging modalities like MRI and CT. In this article the aspects that are needed for the use of current and future therapeutic and diagnostic radiopharmaceuticals are described. Especially the production and development of therapeutic and imageable radiopharmaceuticals are demonstrated. MRI or CT can sometimes also image stable isotopes of elements that contain useful radionuclides. This can result in real multimodality imaging. Combining imaging modalities and imaging agents will result in better patient care and can only be advantageous if all departments and institutes will collaborate on their research work. The combination of approaches together with the fast progress in developments in the medical imaging world will result in a bright future for imaging driven therapy of cancer.
Keywords: holmium, MRI, SPECT, PET/CT, cancer, multimodality, molecular imaging, Radionuclides
Anti-Cancer Agents in Medicinal Chemistry
Title: The Bright Future of Radionuclides for Cancer Therapy
Volume: 7 Issue: 3
Author(s): Johannes Franciscus Wilhelmus Nijsen, Gerard Cornelis Krijger and Afred Dirk van het Schip
Affiliation:
Keywords: holmium, MRI, SPECT, PET/CT, cancer, multimodality, molecular imaging, Radionuclides
Abstract: Originally, nuclear medicine focused on radiopharmaceuticals trapped in organ structures, based on their function, and the presence of disease was seen by the absence of radioactivity. More recently, target-specific radiopharmaceuticals have been developed to visualize and/or treat oncological diseases. Since radiopharmaceuticals have historically a leading position in the search for “molecular imaging”, it would be a waste not to learn from the pitfalls and opportunities that have been and are found during the development of radiopharmaceuticals. This knowledge can be used in the improvement of contrast agents for other imaging modalities like MRI and CT. In this article the aspects that are needed for the use of current and future therapeutic and diagnostic radiopharmaceuticals are described. Especially the production and development of therapeutic and imageable radiopharmaceuticals are demonstrated. MRI or CT can sometimes also image stable isotopes of elements that contain useful radionuclides. This can result in real multimodality imaging. Combining imaging modalities and imaging agents will result in better patient care and can only be advantageous if all departments and institutes will collaborate on their research work. The combination of approaches together with the fast progress in developments in the medical imaging world will result in a bright future for imaging driven therapy of cancer.
Export Options
About this article
Cite this article as:
Franciscus Wilhelmus Nijsen Johannes, Cornelis Krijger Gerard and Dirk van het Schip Afred, The Bright Future of Radionuclides for Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152007780618207
DOI https://dx.doi.org/10.2174/187152007780618207 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anticoagulant and Fibrinolytic Drugs – Possible Agents in Treatment of Lung Cancer?
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Mini-Reviews in Medicinal Chemistry Recent Progress in Delivery of Therapeutic and Imaging Agents Utilizing Organic-Inorganic Hybrid Nanoparticles
Current Drug Delivery Fighting Alzheimer's Disease and Type 2 Diabetes: Pathological links and Treatment Strategies
CNS & Neurological Disorders - Drug Targets Understanding Mouse Skin Carcinogenesis through Transgenic Approaches
Current Genomics Research Highlight: Deoxyribonucleic Acid Based Nanotechnology
Micro and Nanosystems Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design MicroRNAs Regulate the Epithelial to Mesenchymal Transition (EMT) in Cancer Progression
MicroRNA 4,7-Dihydroindole: A Synthon for the Preparations of 2-Substituted Indoles
Current Organic Synthesis Castration Resistant Prostate Cancer (CRPC): State of the Art, Perspectives and New Challenges
Anti-Cancer Agents in Medicinal Chemistry Novel Beta-Lactam Antibiotics Derivatives: Their New Applications as Gene Reporters, Antitumor Prodrugs and Enzyme Inhibitors
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member
Current Cancer Drug Targets Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases
Current Medicinal Chemistry Glycosylated Antitumor Ether Lipids: Activity and Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Retraction Notice: An Outlook on Ovarian Cancer and Borderline Ovarian Tumors: Focus on Genomic and Proteomic Findings
Current Genomics A Sustainable Approach to Bis-Indole Synthesis Using Propylene Carbonate as an Eco-Friendly Solvent
Current Organic Synthesis Effect of Non-Steroidal Anti-Inflammatory Drugs on Bone Turnover: An Evidence-Based Review
Reviews on Recent Clinical Trials Editorial (Thematic Issue: Focal Adhesion Kinase and Cross-Linked Signaling In Cancer)
Anti-Cancer Agents in Medicinal Chemistry Integrin αvβ3 Antagonists for Anti-Angiogenic Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery